# Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

> **NCT00595686** · PHASE1 · COMPLETED · sponsor: **Esanex Inc.** · enrollment: 25 (actual)

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **DRUG:** SNX-5422

## Key facts

- **NCT ID:** NCT00595686
- **Lead sponsor:** Esanex Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2012-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00595686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00595686, "Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00595686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*